Klim McPherson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Klim McPherson has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Dikshyanta Rana
Health Economics and Health Technology Assessment, School of Health and Wellbeing University of Glasgow Glasgow UK
2 shared publications - Fusun Sirkeci
Department of Obstetrics and Gynaecology St Mary's Hospital, Manchester NHS Foundation Trust Manchester UK
2 shared publications - Isaac Manyonda
St George’s University Hospital NHS Foundation Trust, London, UK
2 shared publications - Jane Daniels
Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK
2 shared publications - Jonathan G. Moss
University of Glasgow, Glasgow, United Kingdom (J.G.M.)
2 shared publications - Lee Middleton
Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK
2 shared publications
Latest Publications
- 1 April 2022
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 26 (22) , 1-74
Uterine artery embolisation versus myomectomy for premenopausal women with uterine fibroids wishing to avoid hysterectomy: the FEMME RCT
Background: Uterine fibroids are the most common tumour in women of reproductive age and are associated with heavy menstrual bleeding, abdominal discomfort, subfertility and reduced quality of life. For women wishing to retain their uterus and who do not respond to medical treatment, myomectomy and uterine artery embolisation are therapeutic options. Objectives: We examined the clinical effectiveness and cost-effectiveness of uterine artery embolisation compared with myomectomy in the treatment of symptomatic fibroids. Design: A multicentre, open, randomised trial with a parallel economic evaluation. Setting: Twenty-nine UK hospitals. Participants: Premenopausal women who had symptomatic uterine fibroids amenable to myomectomy or uterine artery embolisation were recruited. Women were excluded if they had significant adenomyosis, any malignancy or pelvic inflammatory disease or if they had already had a previous open myomectomy or uterine artery embolisation. Interventions: Participants were randomised to myomectomy or embolisation in a 1 : 1 ratio using a minimisation algorithm. Myomectomy could be open abdominal, laparoscopic or hysteroscopic. Embolisation of the uterine arteries was performed under fluoroscopic guidance. Main outcome measures: The primary outcome was the Uterine Fibroid Symptom Quality of Life questionnaire (with scores ranging from 0 to 100 and a higher score indicating better quality of life) at 2 years, adjusted for baseline score. The economic evaluation estimated quality-adjusted life-years (derived from EuroQol-5 Dimensions, three-level version, and costs from the NHS perspective). Results: A total of 254 women were randomised – 127 to myomectomy (105 underwent myomectomy) and 127 to uterine artery embolisation (98 underwent embolisation). Information on the primary outcome at 2 years was available for 81% (n = 206) of women. Primary outcome scores at 2 years were 84.6 (standard deviation 21.5) in the myomectomy group and 80.0 (standard deviation 22.0) in the uterine artery embolisation group (intention-to-treat complete-case analysis mean adjusted difference 8.0, 95% confidence interval 1.8 to 14.1, p = 0.01; mean adjusted difference using multiple imputation for missing responses 6.5, 95% confidence interval 1.1 to 11.9). The mean difference in the primary outcome at the 4-year follow-up time point was 5.0 (95% CI –1.4 to 11.5; p = 0.13) in favour of myomectomy. Perioperative and postoperative complications from all initial procedures occurred in similar percentages of women in both groups (29% in the myomectomy group vs. 24% in the UAE group). Twelve women in the uterine embolisation group and six women in the myomectomy group reported pregnancies over 4 years, resulting in seven and five live births, respectively (hazard ratio 0.48, 95% confidence interval 0.18 to 1.28). Over a 2-year time horizon, uterine artery embolisation was associated with higher costs than myomectomy (mean cost £7958, 95% confidence interval £6304 to £9612, vs. mean cost £7314, 95% confidence interval £5854 to £8773), but with fewer quality-adjusted life-years gained (0.74, 95% confidence interval 0.70 to 0.78, vs. 0.83, 95% confidence interval 0.79 to 0.87). The differences in costs (difference £645, 95% confidence interval –£1381 to £2580) and quality-adjusted life-years (difference –0.09, 95% confidence interval –0.11 to –0.04) were small. Similar results were observed over the 4-year time horizon. At a threshold of willingness to pay for a gain of 1 QALY of £20,000, the probability of myomectomy being cost-effective is 98% at 2 years and 96% at 4 years. Limitations: There were a substantial number of women who were not recruited because of their preference for a particular treatment option. Conclusions: Among women with symptomatic uterine fibroids, myomectomy resulted in greater improvement in quality of life than did uterine artery embolisation. The differences in costs and quality-adjusted life-years are very small. Future research should involve women who are desiring pregnancy. Trial registration: This trial is registered as ISRCTN70772394. Funding: This study was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme, and will be published in full in Health Technology Assessment; Vol. 26, No. 22. See the NIHR Journals Library website for further project information.
- 1 April 2022
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 26 (22) , 1-74
Uterine artery embolisation versus myomectomy for premenopausal women with uterine fibroids wishing to avoid hysterectomy: the FEMME RCT
Background: Uterine fibroids are the most common tumour in women of reproductive age and are associated with heavy menstrual bleeding, abdominal discomfort, subfertility and reduced quality of life. For women wishing to retain their uterus and who do not respond to medical treatment, myomectomy and uterine artery embolisation are therapeutic options. Objectives: We examined the clinical effectiveness and cost-effectiveness of uterine artery embolisation compared with myomectomy in the treatment of symptomatic fibroids. Design: A multicentre, open, randomised trial with a parallel economic evaluation. Setting: Twenty-nine UK hospitals. Participants: Premenopausal women who had symptomatic uterine fibroids amenable to myomectomy or uterine artery embolisation were recruited. Women were excluded if they had significant adenomyosis, any malignancy or pelvic inflammatory disease or if they had already had a previous open myomectomy or uterine artery embolisation. Interventions: Participants were randomised to myomectomy or embolisation in a 1 : 1 ratio using a minimisation algorithm. Myomectomy could be open abdominal, laparoscopic or hysteroscopic. Embolisation of the uterine arteries was performed under fluoroscopic guidance. Main outcome measures: The primary outcome was the Uterine Fibroid Symptom Quality of Life questionnaire (with scores ranging from 0 to 100 and a higher score indicating better quality of life) at 2 years, adjusted for baseline score. The economic evaluation estimated quality-adjusted life-years (derived from EuroQol-5 Dimensions, three-level version, and costs from the NHS perspective). Results: A total of 254 women were randomised – 127 to myomectomy (105 underwent myomectomy) and 127 to uterine artery embolisation (98 underwent embolisation). Information on the primary outcome at 2 years was available for 81% (n = 206) of women. Primary outcome scores at 2 years were 84.6 (standard deviation 21.5) in the myomectomy group and 80.0 (standard deviation 22.0) in the uterine artery embolisation group (intention-to-treat complete-case analysis mean adjusted difference 8.0, 95% confidence interval 1.8 to 14.1, p = 0.01; mean adjusted difference using multiple imputation for missing responses 6.5, 95% confidence interval 1.1 to 11.9). The mean difference in the primary outcome at the 4-year follow-up time point was 5.0 (95% CI –1.4 to 11.5; p = 0.13) in favour of myomectomy. Perioperative and postoperative complications from all initial procedures occurred in similar percentages of women in both groups (29% in the myomectomy group vs. 24% in the UAE group). Twelve women in the uterine embolisation group and six women in the myomectomy group reported pregnancies over 4 years, resulting in seven and five live births, respectively (hazard ratio 0.48, 95% confidence interval 0.18 to 1.28). Over a 2-year time horizon, uterine artery embolisation was associated with higher costs than myomectomy (mean cost £7958, 95% confidence interval £6304 to £9612, vs. mean cost £7314, 95% confidence interval £5854 to £8773), but with fewer quality-adjusted life-years gained (0.74, 95% confidence interval 0.70 to 0.78, vs. 0.83, 95% confidence interval 0.79 to 0.87). The differences in costs (difference £645, 95% confidence interval –£1381 to £2580) and quality-adjusted life-years (difference –0.09, 95% confidence interval –0.11 to –0.04) were small. Similar results were observed over the 4-year time horizon. At a threshold of willingness to pay for a gain of 1 QALY of £20,000, the probability of myomectomy being cost-effective is 98% at 2 years and 96% at 4 years. Limitations: There were a substantial number of women who were not recruited because of their preference for a particular treatment option. Conclusions: Among women with symptomatic uterine fibroids, myomectomy resulted in greater improvement in quality of life than did uterine artery embolisation. The differences in costs and quality-adjusted life-years are very small. Future research should involve women who are desiring pregnancy. Trial registration: This trial is registered as ISRCTN70772394. Funding: This study was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme, and will be published in full in Health Technology Assessment; Vol. 26, No. 22. See the NIHR Journals Library website for further project information.
- Open Access
- 30 May 2021
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 128 (11) , 1793-1802
Uterine artery embolisation or myomectomy for women with uterine fibroids wishing to avoid hysterectomy: a cost–utility analysis of the FEMME trial
Objectives: To assess the cost‐effectiveness of uterine artery embolisation (UAE) and myomectomy for women with symptomatic uterine fibroids wishing to avoid hysterectomy.Design: Economic evaluation alongside the FEMME randomised controlled trial.Setting: 29 UK hospitals.Population: Premenopausal women who had symptomatic uterine fibroids amenable to UAE or myomectomy wishing to avoid hysterectomy. 254 women were randomised to UAE (127) and myomectomy (127).Methods: A within‐trial cost–utility analysis was conducted from the perspective of the UK NHS.Main outcome measures: Quality‐adjusted life years (QALYs) measured using the EuroQoL EQ‐5D‐3L, combined with costs to estimate cost‐effectiveness over 2 and 4 years of follow‐up.Results: Over a 2‐year time horizon, UAE was associated with higher mean costs (difference £645; 95% CI −1381 to 2580) and lower QALYs (difference −0.09; 95% CI −0.11 to −0.04) when compared with myomectomy. Similar results were observed over the 4‐year time horizon. Thus, UAE was dominated by myomectomy. Results of the sensitivity analyses were consistent with the base case results for both years. Over 2 years, UAE was associated with higher costs (difference £456; 95% CI −1823 to 3164) and lower QALYs (difference −0.06; 95% CI −0.11 to −0.02).Conclusions: Myomectomy is a cost‐effective option for the treatment of uterine fibroids. The differences in costs and QALYs are small. Women should be fully informed and have the option to choose between the two procedures.Tweetable Fully informed women with uterine fibroids should have a choice between uterine artery embolisation or myomectomy.
- 30 May 2021
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 128 (11) , 1793-1802
Open AccessUterine artery embolisation or myomectomy for women with uterine fibroids wishing to avoid hysterectomy: a cost–utility analysis of the FEMME trial
Objectives: To assess the cost‐effectiveness of uterine artery embolisation (UAE) and myomectomy for women with symptomatic uterine fibroids wishing to avoid hysterectomy.Design: Economic evaluation alongside the FEMME randomised controlled trial.Setting: 29 UK hospitals.Population: Premenopausal women who had symptomatic uterine fibroids amenable to UAE or myomectomy wishing to avoid hysterectomy. 254 women were randomised to UAE (127) and myomectomy (127).Methods: A within‐trial cost–utility analysis was conducted from the perspective of the UK NHS.Main outcome measures: Quality‐adjusted life years (QALYs) measured using the EuroQoL EQ‐5D‐3L, combined with costs to estimate cost‐effectiveness over 2 and 4 years of follow‐up.Results: Over a 2‐year time horizon, UAE was associated with higher mean costs (difference £645; 95% CI −1381 to 2580) and lower QALYs (difference −0.09; 95% CI −0.11 to −0.04) when compared with myomectomy. Similar results were observed over the 4‐year time horizon. Thus, UAE was dominated by myomectomy. Results of the sensitivity analyses were consistent with the base case results for both years. Over 2 years, UAE was associated with higher costs (difference £456; 95% CI −1823 to 3164) and lower QALYs (difference −0.06; 95% CI −0.11 to −0.02).Conclusions: Myomectomy is a cost‐effective option for the treatment of uterine fibroids. The differences in costs and QALYs are small. Women should be fully informed and have the option to choose between the two procedures.Tweetable Fully informed women with uterine fibroids should have a choice between uterine artery embolisation or myomectomy.
- Open Access
- 1 November 2020
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 6 (6) , 1772-1790
Mammographic Screening in the Occupied Palestinian Territory: A Critical Analysis of Its Promotion, Claimed Benefits, and Safety in Palestinian Health Research
PURPOSE: To critically review the evidence and opinions expressed about mammographic screening (MS) in research reports on breast cancer in the occupied Palestinian territory (oPt) and to assess whether benefits and harms in MS are presented in a balanced way. METHODS: Searches of PubMed, Cochrane, MEDLINE, EMBASE, CINAHL, and gray literature identified 14 eligible research reports relating to the oPt. We reviewed these documents and then used a thematic analysis to describe and analyze the evidence and the opinions about MS expressed in them. RESULTS: All 14 research reports mentioned that MS would improve survival rates in the oPt. Only three gave information on major harmful effects, and only two emphasized that MS must be accompanied by effective treatment to have any beneficial effects on population mortality. There was no consistency in the recommended frequency of MS. CONCLUSION: Most information presented by Palestinian health researchers was selective and failed to address the important established harms of MS. Thus, calls to support MS in the oPt are not based on a measured discussion of the risks and benefits for women or grounded in the systemic readiness of health care necessary for its effectiveness. As long as diagnostic and treatment facilities remain deficient, screening cannot lead to reduced mortality from breast cancer.
- 1 November 2020
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 6 (6) , 1772-1790
Open AccessMammographic Screening in the Occupied Palestinian Territory: A Critical Analysis of Its Promotion, Claimed Benefits, and Safety in Palestinian Health Research
PURPOSE: To critically review the evidence and opinions expressed about mammographic screening (MS) in research reports on breast cancer in the occupied Palestinian territory (oPt) and to assess whether benefits and harms in MS are presented in a balanced way. METHODS: Searches of PubMed, Cochrane, MEDLINE, EMBASE, CINAHL, and gray literature identified 14 eligible research reports relating to the oPt. We reviewed these documents and then used a thematic analysis to describe and analyze the evidence and the opinions about MS expressed in them. RESULTS: All 14 research reports mentioned that MS would improve survival rates in the oPt. Only three gave information on major harmful effects, and only two emphasized that MS must be accompanied by effective treatment to have any beneficial effects on population mortality. There was no consistency in the recommended frequency of MS. CONCLUSION: Most information presented by Palestinian health researchers was selective and failed to address the important established harms of MS. Thus, calls to support MS in the oPt are not based on a measured discussion of the risks and benefits for women or grounded in the systemic readiness of health care necessary for its effectiveness. As long as diagnostic and treatment facilities remain deficient, screening cannot lead to reduced mortality from breast cancer.
- Open Access
- 1 May 2017
- Published by Elsevier in The Lancet Public Health
- Vol. 2 (5) , e203-e204
The costs of overweight
- 1 May 2017
- Published by Elsevier in The Lancet Public Health
- Vol. 2 (5) , e203-e204
Open AccessThe costs of overweight
- Open Access
- 5 August 2011
- Published by BMJ in Journal of Epidemiology and Community Health
- Vol. 65 (Suppl 1) , A345.3-A345
P2-451 What will be the impact of current trends of obesity in Brazil and Mexico on their future healthcare demands
Introduction Brazil and Mexico are two of the fastest growing economies in the world. Mexico currently has one of the largest prevalence's of obesity in the world 24.2% for men and 34.5% for women in 2006 while Brazil has much lower levels of 8.9% and 13.1% (2003 figures). What will be the future impact of these trends particularly for their respective healthcare systems. Methods Utilising the method developed for the Foresight Tackling Obesities study in the UK. The authors firstly predict future trends based on current data and then by feeding those into a micro-simulation programme developed by the NHF calculate future attributable disease burdens and their attendant health costs based on these trends and is able to test various future scenarios. Results If unchecked the rates of increase of obesity in Mexico, will mean it faces an unsustainable attributable disease burdens and attendant health costs. If significant policies are enacted to ameliorate these trends then even relatively small population reductions in BMI could have significant health benefits to the population. Brazil though lagging behind could soon have unsustainable obesity levels too if nothing is done. The example of Mexico should offer a wake up call for Brazilian health policy makers and others in the region as to what the future impact of ignoring a rise in obesity trends will be. Conclusion As yet there is little evidence of the effectiveness of national policies to stem the rise in obesity but this study shows even small population changes can have substantial savings to a countries future healthcare costs.
- 5 August 2011
- Published by BMJ in Journal of Epidemiology and Community Health
- Vol. 65 (Suppl 1) , A345.3-A345
Open AccessP2-451 What will be the impact of current trends of obesity in Brazil and Mexico on their future healthcare demands
Introduction Brazil and Mexico are two of the fastest growing economies in the world. Mexico currently has one of the largest prevalence's of obesity in the world 24.2% for men and 34.5% for women in 2006 while Brazil has much lower levels of 8.9% and 13.1% (2003 figures). What will be the future impact of these trends particularly for their respective healthcare systems. Methods Utilising the method developed for the Foresight Tackling Obesities study in the UK. The authors firstly predict future trends based on current data and then by feeding those into a micro-simulation programme developed by the NHF calculate future attributable disease burdens and their attendant health costs based on these trends and is able to test various future scenarios. Results If unchecked the rates of increase of obesity in Mexico, will mean it faces an unsustainable attributable disease burdens and attendant health costs. If significant policies are enacted to ameliorate these trends then even relatively small population reductions in BMI could have significant health benefits to the population. Brazil though lagging behind could soon have unsustainable obesity levels too if nothing is done. The example of Mexico should offer a wake up call for Brazilian health policy makers and others in the region as to what the future impact of ignoring a rise in obesity trends will be. Conclusion As yet there is little evidence of the effectiveness of national policies to stem the rise in obesity but this study shows even small population changes can have substantial savings to a countries future healthcare costs.
- 1 September 2004
- Published by Mark Allen Group in International Journal of Therapy and Rehabilitation
- Vol. 11 (9) , 435-440
Impact of the introduction of a multidisciplinary weaning team on a general intensive care unit
- 1 September 2004
- Published by Mark Allen Group in International Journal of Therapy and Rehabilitation
- Vol. 11 (9) , 435-440
Impact of the introduction of a multidisciplinary weaning team on a general intensive care unit
- Open Access
- 23 September 2002
- Published by Hindawi Limited in European Journal of Cancer Care
- Vol. 11 (3) , 225-231
Quantitative and qualitative methods in UK health research: then, now and . . . ?
This paper examines the current status of qualitative and quantitative research in the context of UK (public) health research in cancer. It is proposed that barren competition between qualitative and quantitative methods is inevitable, but that effective synergy between them continues to be essential to research excellence. The perceived methodological utility, with respect to understanding residual uncertainties, can account for the status accorded various research techniques and these will help to explain shifts witnessed in recent years and contribute towards an understanding of what can be realistically expected in terms of future progress. It is argued that the methodological debate, though familiar to many, is worthy of rearticulation in the context of cancer research where the psychosocial aspects of living with a cancer and the related complexity of providing appropriate cancer care are being addressed across Europe, as evidenced in recent directions in policy and research.
- 23 September 2002
- Published by Hindawi Limited in European Journal of Cancer Care
- Vol. 11 (3) , 225-231
Open AccessQuantitative and qualitative methods in UK health research: then, now and . . . ?
This paper examines the current status of qualitative and quantitative research in the context of UK (public) health research in cancer. It is proposed that barren competition between qualitative and quantitative methods is inevitable, but that effective synergy between them continues to be essential to research excellence. The perceived methodological utility, with respect to understanding residual uncertainties, can account for the status accorded various research techniques and these will help to explain shifts witnessed in recent years and contribute towards an understanding of what can be realistically expected in terms of future progress. It is argued that the methodological debate, though familiar to many, is worthy of rearticulation in the context of cancer research where the psychosocial aspects of living with a cancer and the related complexity of providing appropriate cancer care are being addressed across Europe, as evidenced in recent directions in policy and research.
- 1 October 1999
- Published by Elsevier in European Journal of Cancer
- Vol. 35 (11) , 1598-1602
The impact of patient treatment preferences on the interpretation of randomised controlled trials
- 1 October 1999
- Published by Elsevier in European Journal of Cancer
- Vol. 35 (11) , 1598-1602
The impact of patient treatment preferences on the interpretation of randomised controlled trials